THRX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 46.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Theseus Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Theseus Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Theseus Pharmaceuticals Share Price & Price History
Current Price: $4.06
Price Change: +0.30 (1.20%)
As of 02/14/2024 01:00 AM ET
Theseus Pharmaceuticals Insider Trading History
Theseus Pharmaceuticals Institutional Trading History
Data available starting January 2016
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Read More on Theseus Pharmaceuticals
Volume
N/A
Average Volume
592,167 shs
Market Capitalization
$179.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.98
Who are the company insiders with the largest holdings of Theseus Pharmaceuticals?